AnaptysBio director exercises 6,030 RSUs into shares

AnaptysBio director Renton Hollings reported a routine equity compensation event.

Rhea-AI Filing Summary

AnaptysBio director Renton Hollings reported a routine equity compensation event. On June 15, 2026, he exercised 6,030 restricted stock units (RSUs), receiving 6,030 shares of common stock for no cash consideration, as each RSU converts into one share upon settlement.

Following this RSU settlement, Hollings directly holds 10,995 shares of AnaptysBio common stock. The RSU award vested 100% on June 15, 2026, conditioned on continued service through the vesting date, so this transaction reflects compensation vesting rather than an open‑market purchase or sale.

Insider Trade Summary

6,030 shares exercised/converted

Exercise 2 txns

Insider RENTON HOLLINGS

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,030	$0.00	$0.00
Exercise	Common Stock	6,030	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 10,995 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

RSUs exercised: 6,030 shares Shares received: 6,030 shares Post-transaction holdings: 10,995 shares +2 more

5 metrics

RSUs exercised 6,030 shares Restricted stock units settled into common stock on June 15, 2026

Shares received 6,030 shares Common stock received upon RSU settlement for no consideration

Post-transaction holdings 10,995 shares Common stock directly held by Renton Hollings after the transaction

Exercise price $0.00 per share RSUs convert to common stock with no cash consideration

Vesting date June 15, 2026 RSU award vested 100% on this date, subject to continued service

Key Terms

Restricted Stock Unit, RSU, derivative security, contingent right

4 terms

Restricted Stock Unit financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AnaptysBio (ANAB) director Renton Hollings report?

AnaptysBio director Renton Hollings reported the vesting and settlement of 6,030 restricted stock units into 6,030 common shares. This was a compensation-related conversion at no cash cost, not an open-market purchase or sale of AnaptysBio stock.

How many AnaptysBio (ANAB) shares does Renton Hollings hold after this Form 4?

After this Form 4 transaction, Renton Hollings directly holds 10,995 shares of AnaptysBio common stock. This reflects his equity position following the conversion of 6,030 restricted stock units that vested and settled into common shares on June 15, 2026.

Was cash paid for the 6,030 AnaptysBio (ANAB) shares received by Renton Hollings?

No cash was paid for these 6,030 AnaptysBio shares. Each restricted stock unit represented a contingent right to receive one share of common stock upon settlement for no consideration, so the shares were issued as part of Hollings’ equity compensation.

When did Renton Hollings’ restricted stock units in AnaptysBio (ANAB) vest?

The restricted stock units vested 100% on June 15, 2026. Vesting was conditioned on Renton Hollings continuing to provide service to AnaptysBio through that date, after which the 6,030 RSUs settled into an equal number of common shares at no cash cost.

Does this AnaptysBio (ANAB) Form 4 show any insider share sales by Renton Hollings?

The Form 4 does not show any share sales by Renton Hollings. It reports the exercise and settlement of 6,030 restricted stock units into common stock, a compensation-related equity conversion, with no indicated open-market selling transaction in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RENTON HOLLINGS

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M		6,030	A	$0(1)	10,995	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/15/2026		M			6,030	(2)	(2)	Common Stock	6,030	$0	0	D

Explanation of Responses:

1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Christopher Murphy, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)